Veterinary Medicines Directorate

United Kingdom
Veterinary Medicines Directorate
Woodham Lane
New Haw
Addlestone
Surrey KT15 3LS

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Intubeaze 20 mg/ml Laryngopharyngeal Spray, Solution for Cats

Date Created: November 2018

MODULE 1

PRODUCT SUMMARY

EU Procedure number	UK/V/0670/001/DC
Name, strength and pharmaceutical form	Intubeaze 20 mg/ml Laryngopharyngeal Spray, Solution for Cats
Applicant	Dechra Limited, Snaygill Industrial Estate, Keighley Road, Skipton, North Yorkshire, BD23 2RW
Active substance(s)	Lidocaine Hydrochloride
ATC Vetcode	QR02AD02
Target species	Cats
Indication for use	Local anaesthesia of the laryngeal mucosa of the cat in order to facilitate endotracheal intubation by preventing the stimulation of the laryngeal reflex.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Product Information Database of the Veterinary Medicines Directorate.

(www.gov.uk/check-animal-medicine-licensed)

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended by 2004/28/EC
Date of conclusion of the decentralised procedure	26 September 2018
Date product first authorised in the Reference Member State (MRP only)	Not Applicable
Concerned Member States for original procedure	Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Spain, Sweden

I. SCIENTIFIC OVERVIEW

This was an application for a generic product, submitted in accordance with Article 13(1) of Directive 2001/82/EC, as amended by 2004/28/EC.

The reference product is Intubeaze 20 mg/ml Oromucosal Spray for Cats, authorised in the UK since September 1996.

The product is indicated for local anaesthesia of the laryngeal mucosa of the cat in order to facilitate endotracheal intubation by preventing the stimulation of the laryngeal reflex.

The product contains lidocaine hydrochloride monohydrate at 20 mg/ml, (equivalent to lidocaine 16.2 mg). Each actuation (0.14 ml contains 2.8 mg of lidocaine hydrochloride monohydrate, which corresponds to 2.27 mg of lidocaine. The product is administered via one or two sprays to the back of the throat.

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released onto the market. It has been shown that the product can be safely used in the target species, any reactions observed are indicated in the SPC.[1] The product is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy [2] of the product was demonstrated according to the claims made in the SPC.
The overall benefit/risk analysis is in favour of granting a marketing

[1] SPC – Summary of product Characteristics.
[2] Efficacy – The production of a desired or intended result.

authorisation.

II. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS

II.A. Composition

The product contains lidocaine hydrochloride and the excipients sodium chloride, chlorocresol and water for injections.

The container/closure system consists of type 1 clear glass vials sealed with a spray pump. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation and the presence of preservative are not justified. This is the same as the reference product, therefore acceptable.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

II.B. Description of the Manufacturing Method

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The manufacturing method consists of a simple dissolution process whereby the excipients are dissolved then heated to 50 - 60 ºC. Once cooled, the active substance is then added and dissolved. The solution is made to volume with water for injections and re-mixed.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

II.C. Control of Starting Materials

The active substance is lidocaine hydrochloride an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided. Suitable Certificates of Analysis were provided.

All excipients are monographed within the European Pharmacopoeia (Ph. Eur).

The container for the product is a glass vial sealed with a spray pump.

II.C.4. Substances of Biological Origin

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process

Not applicable

II.E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production sites have been provided demonstrating compliance with the specification. Control tests on the finished product include those for: description, identification, pH, assay, average spray volume, spray uniformity, spray pattern, total viable count, absence of *Pseudomonas aeruginosa* and *Staphylococcus aureus*.

II.F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

G. Other Information

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening: 3 months
The product should not be stored above 25°C

III. SAFETY AND RESIDUES DOCUMENTATION (PHARMACO-TOXICOLOGICAL)

III.A Safety Documentation

Pharmacological Studies

Due to the legal basis of this application, pharmacological and toxicological data are not required, other than to support the user risk assessment (URA).

Toxicological Studies

Due to the legal basis of this application, pharmacological and toxicological data are not required, other than to support the user risk assessment (URA).

User Safety

A user risk assessment was provided in compliance with the relevant guideline which shows that the product will only be administered by veterinarians or similarly qualified people and will only be used in veterinary clinics or similar controlled environments.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product. Therefore the following applicant's user recommendations are appropriate:

- Lidocaine and Chlorocresol may cause hypersensitivity (allergic) reactions. People with known hypersensitivity to these substances should avoid contact with the product.
- Accidental exposure to this product may lead to local effects such as numbing, and systemic effects, such as dizziness or drowsiness. Accidental exposure, particularly oral, eye and inhalation exposure, should be avoided.
- Wear gloves when handling the product and wash any exposed areas after use. If accidental exposure to eyes occurs, rinse with water.
- In cases of severe or extended reactions, seek medical advice and show the label to the physician.
- Lidocaine can form genotoxic and mutagenic metabolites in humans. These metabolites can also induce, in long-term toxicology studies in rats, carcinogenic effects at high doses.

Environmental Safety

The applicant has submitted a Phase I ERA conducted in accordance with current VICH and CVMP guidelines. The assessment has concluded at question 3 of the decision tree, as the product will be used in non-food producing animals only. A Phase II ERA was not required.

The disposal advice and environmental warnings found under section 6.6 of the SPC and package leaflet are as follows:

- Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

IV CLINICAL DOCUMENTATION

IV.I. Pre-Clinical Studies

Pharmacology

As this product is a generic, the applicant has not provided data pharmacodynamic and pharmacokinetic properties of the active substance.

Tolerance in the Target Species

Tolerance studies were not required as this is a generic product.

IV.II. Clinical Documentation

Laboratory Trials

The applicant has not provided any studies as this is a generic product.

V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics the benefit/risk profile of the product is favourable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)